InvestSMART

Argent Biopharma Limited (ASX:RGT)

ALERT: Price-sensitive ASX Announcement for RGT
Current share price for RGT : $0.028 -0.028 (-50%)+
Announcement
Release
27 Feb 2026 6:15PM
Price at Release
$0.056
Full Release
download
Summary
Argent BioPharma Ltd's consolidated interim financial report for the half-year ended 31 December 2025 reports a reduced net loss of A$2.9 million compared to the previous year. No dividends were declared. Key developments include a strategic acquisition agreement with AusCann to advance their drug development pipeline, and a U.S. study validating ArtemiC™'s efficacy. Despite financial losses, Argent secured substantial financing to support ongoing initiatives and reported positive cash flows from financing activities. The period also saw the liquidation of the Slovenian subsidiary, reflecting strategic operational changes.
Key Points
  • Argent BioPharma Ltd incurred a net loss of A$2.9 million for the half-year ended 31 December 2025.
  • No dividends were declared or paid during this financial period.
  • Argent signed a binding agreement to acquire AusCann assets to enhance strategic drug development.
  • Successful completion of an independent U.S. study demonstrated ArtemiC™ efficacy in viral models.
  • Argent secured financing agreements providing up to A$11 million for strategic initiatives.
  • The company experienced significant cash flows from financing activities, enhancing liquidity.
  • A loss was recognized due to the liquidation of its Slovenian subsidiary, Argent BioPharma d.o.o.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.